A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced Cancer.
| Image |  |
|---|---|
| Description | scientific article published on 18 November 2015 |
| Author/s |
author: Xuekui Zhang Julian R Molina Paul Haluska Matthew P Goetz Charles Erlichman |
| Publication date | November 18, 2015 |
| Language | English |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |